Istuti Saraswat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Istuti Saraswat has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anjana Goel
GLA University, Mathura, India
4 shared publications Ayushi Sharma
Instituteof Molecular Biology, Academia Sinica, Taipei, Taiwan
1 shared publicationJaikishan Chaudhary
Department of Biologics Division, Dr. Reddy's Laboratories,Hyderabad, India
1 shared publicationJyoti Gupta
Department of Biotechnology, GLA University, 17km Stone, NH_19 Mathura-Delhi Road, Chaumuhan,Mathura, Uttar Pradesh, India
1 shared publication- Jyoti Gupta
Department of Biotechnology, GLA University, Mathura, India
1 shared publication Rijul Joshi
Department of Biotechnology, GLA University, 17km Stone, NH-19, Mathura-Delhi Road, P.O. Chaumuhan, Mathura-281 406, (U.P.) India
1 shared publication
Latest Publications
- 21 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (10) , 643
Deciphering the Anti-oxidant and Anti-Inflammatory Activities of Green-Synthesized Silver Nanoparticles from Argemone mexicana Linn
- 21 September 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (10) , 643
Deciphering the Anti-oxidant and Anti-Inflammatory Activities of Green-Synthesized Silver Nanoparticles from Argemone mexicana Linn
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26 (1) , 39-50
Nanotechnology Meets Phytotherapy: A Comprehensive Review of Berberine in Cancer
Cancer continues to pose a worldwide health concern, requiring breakthrough therapeutic approaches that are both efficacious and minimally intrusive. Berberine, a natural isoquinoline alkaloid, has attracted considerable interest due to its various pharmacological features, particularly its strong anticancer effects. Nonetheless, its clinical application has been impeded by inadequate bioavailability, rapid metabolism, and systemic elimination. Recent breakthroughs in nanotechnology have mitigated these issues by creating BBR nanoparticles (BBR NPs), which provide increased solubility, precise delivery, and higher therapeutic efficacy. This paper extensively examines BBR and its nanoparticle forms for cancer treatment. The mechanisms of action, including apoptosis induction, tumour angiogenesis inhibition, antimetastatic effects, and oxidative stress modulation, are thoroughly examined. Essential synthesis approaches for BBR nanoparticles, including chemical reduction, green synthesis, and encapsulation in nanocarriers, are discussed together with their characterization methodologies. The report emphasizes comparative studies that illustrate the enhanced antitumor efficacy of BBR nanoparticles compared to free BBR in preclinical settings. Notwithstanding encouraging results, nanoparticle stability, scalability, and regulatory obstacles must be resolved for effective clinical translation. Future directions are examined, encompassing advancements in nanoparticle design and their prospective incorporation into personalized oncology. This review highlights the transforming potential of BBR and its nanoformulations as a novel therapeutic approach in cancer treatment.
- 1 January 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26 (1) , 39-50
Nanotechnology Meets Phytotherapy: A Comprehensive Review of Berberine in Cancer
Cancer continues to pose a worldwide health concern, requiring breakthrough therapeutic approaches that are both efficacious and minimally intrusive. Berberine, a natural isoquinoline alkaloid, has attracted considerable interest due to its various pharmacological features, particularly its strong anticancer effects. Nonetheless, its clinical application has been impeded by inadequate bioavailability, rapid metabolism, and systemic elimination. Recent breakthroughs in nanotechnology have mitigated these issues by creating BBR nanoparticles (BBR NPs), which provide increased solubility, precise delivery, and higher therapeutic efficacy. This paper extensively examines BBR and its nanoparticle forms for cancer treatment. The mechanisms of action, including apoptosis induction, tumour angiogenesis inhibition, antimetastatic effects, and oxidative stress modulation, are thoroughly examined. Essential synthesis approaches for BBR nanoparticles, including chemical reduction, green synthesis, and encapsulation in nanocarriers, are discussed together with their characterization methodologies. The report emphasizes comparative studies that illustrate the enhanced antitumor efficacy of BBR nanoparticles compared to free BBR in preclinical settings. Notwithstanding encouraging results, nanoparticle stability, scalability, and regulatory obstacles must be resolved for effective clinical translation. Future directions are examined, encompassing advancements in nanoparticle design and their prospective incorporation into personalized oncology. This review highlights the transforming potential of BBR and its nanoformulations as a novel therapeutic approach in cancer treatment.
- 3 December 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22 (5) , 501-520
From Microbes to Medicine: Bacteriotherapy's Emerging Role in Cancer Treatment Strategies
Cancer, a prominent cause of death, continues to pose difficulties for traditional treatment methods due to the development of resistance in cancer cells. Despite the advances made in technology, the gradual and harmful growth of tumors sometimes results in death, which emphasizes the restrictions of current treatment methods. Bacteriotherapy, a treatment approach that uses bacteria, has become more important in cancer therapies as a reaction to these obstacles. This review examines the diverse use of bacteriotherapy in treating cancer, taking advantage of its inherent benefits compared to other approaches. Although some disease-causing bacteria have been linked to the development of tumors, a significant finding indicates that certain bacterial toxins and peptides possess exceptional abilities to combat cancer. Certain bacterial species, highly skilled at establishing themselves in solid tumors, have shown the capability to effectively regulate the abnormal growth of cancer cells, suppressing tumor advancement and leading to its eventual elimination from the body. Genetically edited bacteria, such as Streptococcus, E. coli, and Streptococcus pyogenes, have attracted attention due to their therapeutic effects in animal models and ongoing human trials. These genetically engineered bacterial strains have been designed to better colonize tumors. They are weakened and altered to be live and can reproduce within tumors. Significantly, genetically engineered bacterial species that are not harmful to humans are remarkable due to their strong attraction and specificity towards cancer cells, which greatly contributes to their impressive effectiveness in treating cancer.
- 3 December 2025
- Published by Bentham Science Publishers Ltd. in Current Cancer Therapy Reviews
- Vol. 22 (5) , 501-520
From Microbes to Medicine: Bacteriotherapy's Emerging Role in Cancer Treatment Strategies
Cancer, a prominent cause of death, continues to pose difficulties for traditional treatment methods due to the development of resistance in cancer cells. Despite the advances made in technology, the gradual and harmful growth of tumors sometimes results in death, which emphasizes the restrictions of current treatment methods. Bacteriotherapy, a treatment approach that uses bacteria, has become more important in cancer therapies as a reaction to these obstacles. This review examines the diverse use of bacteriotherapy in treating cancer, taking advantage of its inherent benefits compared to other approaches. Although some disease-causing bacteria have been linked to the development of tumors, a significant finding indicates that certain bacterial toxins and peptides possess exceptional abilities to combat cancer. Certain bacterial species, highly skilled at establishing themselves in solid tumors, have shown the capability to effectively regulate the abnormal growth of cancer cells, suppressing tumor advancement and leading to its eventual elimination from the body. Genetically edited bacteria, such as Streptococcus, E. coli, and Streptococcus pyogenes, have attracted attention due to their therapeutic effects in animal models and ongoing human trials. These genetically engineered bacterial strains have been designed to better colonize tumors. They are weakened and altered to be live and can reproduce within tumors. Significantly, genetically engineered bacterial species that are not harmful to humans are remarkable due to their strong attraction and specificity towards cancer cells, which greatly contributes to their impressive effectiveness in treating cancer.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25 (5) , 1-15
Harnessing Nanotechnology and Gene Editing for Cancer Therapy: ASynergistic Approach to Precision Medicine
The fusion of nanotechnology with gene editing promises a revolutionary strategy in combating cancer, providing the possibility of precise and focused treatments. This review examines the synergistic integration of these two potent technologies, specifically emphasising their combined effectiveness in oncological therapies. Nanotechnology offers a flexible framework for administering gene-editing tools, improving their accuracy, and reducing unintended side effects, all of which are significant obstacles in existing cancer treatments. Nanoparticles can improve the effectiveness of therapies, lower the risk of systemic toxicity, and allow the simultaneous manipulation of many genetic pathways involved in cancer growth by delivering CRISPR-Cas9 and other gene-editing systems directly to tumour sites. We conduct a thorough analysis of recent progress in this burgeoning field, emphasising significant advancements in the design of nanoparticles and gene-editing techniques that propel the development of next-generation cancer medicines. In addition, we address the present obstacles and constraints, such as the effectiveness of delivery, apprehensions over safety, and regulatory obstacles, while suggesting potential areas of future research to surmount these barriers. This study thoroughly examines the promise of nano-precision gene editing as a transformative approach to cancer treatment by incorporating findings from recent clinical trials and case studies. By highlighting recent clinical advancements and emerging innovations, this review underscores the potential of nano-precision gene editing as a groundbreaking approach in next-generation cancer therapy.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Gene Therapy
- Vol. 25 (5) , 1-15
Harnessing Nanotechnology and Gene Editing for Cancer Therapy: ASynergistic Approach to Precision Medicine
The fusion of nanotechnology with gene editing promises a revolutionary strategy in combating cancer, providing the possibility of precise and focused treatments. This review examines the synergistic integration of these two potent technologies, specifically emphasising their combined effectiveness in oncological therapies. Nanotechnology offers a flexible framework for administering gene-editing tools, improving their accuracy, and reducing unintended side effects, all of which are significant obstacles in existing cancer treatments. Nanoparticles can improve the effectiveness of therapies, lower the risk of systemic toxicity, and allow the simultaneous manipulation of many genetic pathways involved in cancer growth by delivering CRISPR-Cas9 and other gene-editing systems directly to tumour sites. We conduct a thorough analysis of recent progress in this burgeoning field, emphasising significant advancements in the design of nanoparticles and gene-editing techniques that propel the development of next-generation cancer medicines. In addition, we address the present obstacles and constraints, such as the effectiveness of delivery, apprehensions over safety, and regulatory obstacles, while suggesting potential areas of future research to surmount these barriers. This study thoroughly examines the promise of nano-precision gene editing as a transformative approach to cancer treatment by incorporating findings from recent clinical trials and case studies. By highlighting recent clinical advancements and emerging innovations, this review underscores the potential of nano-precision gene editing as a groundbreaking approach in next-generation cancer therapy.